Latest news : Gamida Cell Ltd.

26/05/25	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/07/24	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/06/24	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/06/24	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/06/24	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
17/06/24	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
23/05/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/04/24	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
04/04/24	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/03/24	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/03/24	Top Premarket Decliners	MT
27/03/24	Top Midday Decliners	MT
27/03/24	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations : Gamida Cell Ltd.

29/01/24	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/11/23	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/11/23	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/05/23	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/05/23	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases : Gamida Cell Ltd.

27/03/24	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/03/24	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/03/24	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/02/24	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/01/24	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors : Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	31/05/2021
Ronit Simantov CTO	Chief Tech/Sci/R&D Officer	61	30/06/2017

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	31/03/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets 17:54:51 24/05/2024 BST			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	2.62M 2.25M 2.12M 1.93M 3.62M 248M 3.63M 25.11M 9.71M 127M 9.83M 9.62M 404M	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	39.01M 33.55M 31.55M 28.8M 53.87M 3.69B 54.04M 374M 145M 1.89B 146M 143M 6.02B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.23
5 years	0.01	4.72
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
31/01/24	Ivan Borrello	Free	Director	200,000	0.1508%
31/01/24	Kenneth Moch	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.50%	2.62M
WUXI APPTEC CO., LTD.	-0.38%	-0.99%	+42.69%	+100.85%	67.82B
ARGENX SE	-0.41%	-2.35%	+33.47%	+78.54%	63.22B
INSMED INCORPORATED	-0.31%	+3.67%	-12.96%	+374.95%	27.58B
BIONTECH SE	+0.86%	+2.12%	-7.74%	-13.34%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	+1.69%	-0.36%	+26.48%	+15.46%	25.38B
GENMAB A/S	+1.17%	+1.07%	+24.78%	-17.65%	19.89B
PHARMAESSENTIA CORPORATION	+1.15%	-5.02%	+219.82%	+379.02%	17.4B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.49%	-0.37%	-7.31%	+524.84%	14.95B
EXELIXIS, INC.	-0.20%	+8.00%	+55.78%	+167.98%	14.62B
Average	+0.55%	+1.87%	+37.50%	+151.22%	27.69B
Weighted average by Cap.	+0.07%	+0.90%	+36.65%	+139.89%

Gamida Cell Ltd. Share Price

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation : Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations : Gamida Cell Ltd.

Press Releases : Gamida Cell Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

	2022	2023
Net sales	-	1.78 1.53 1.44 1.32 2.46 168.72 2.47 17.11 6.61 86.4 6.7 6.55 275.21
Net income	-79.38M -68.26M -64.2M -58.61M -110M -7.51B -110M -761M -294M -3.84B -298M -292M -12.25B	-63M -54.18M -50.95M -46.51M -86.99M -5.96B -87.27M -604M -234M -3.05B -237M -231M -9.72B
Net Debt	39.31M 33.8M 31.79M 29.02M 54.28M 3.72B 54.46M 377M 146M 1.9B 148M 144M 6.06B	36.39M 31.29M 29.43M 26.87M 50.25M 3.44B 50.41M 349M 135M 1.76B 137M 134M 5.61B